PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called “Wnt3a alternative peptide (β-catenin pathway agonist)” which has equivalent function to recombinant Wnt3a as well as GSK-3β inhibitors, such as CHIR99021(CHIR)). This product will be available in the middle of November 2023. [Read more…]
VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600M Japanese yen ($4M USD) through Third-Party Allotment
Cumulative Funds Raised Amount to Approximately 1.7 billion yen (Approximately $11.3 million USD)
KOBE, Japan — VCCT Inc. (President: Masayo Takahashi) is pleased to announce the completion of a private equity allotment of approximately 600 million yen ($4 million USD). The allotment involved new shares to Sysmex Corporation (President: Kaoru Asano), DAI-DAN CO., LTD. (Representative Director, President: Ichiro Fujisawa), and YASKAWA Electric Corporation (Representative Director, President: Masahiro Ogawa). VCCT will continue to accelerate the development of retinal regenerative medicine together with these partners. [Read more…]
Ajinomoto Co. to Acquire Gene Therapy CDMO Forge Biologics for an Astounding $620 Million
- Acquisition extends global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc., diversifying and strengthening their current contract development and manufacturing services
- Positions Forge Biologics for accelerated long-term growth supporting gene and cell therapy clients worldwide
Atsena Therapeutics Receives FDA RMAT Designation for ATSN-101 Gene Therapy
RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients with LCA1
ATSN-101 has demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post-treatment in ongoing Phase I/II clinical trial
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
TORONTO and HAIFA, Israel — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for its ExoPTEN therapy, recognizing the potential of this groundbreaking regenerative therapy for acute spinal cord injury, a condition where effective treatments are limited. [Read more…]
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 119
- Next Page »